Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Continuous flow reactions using fixed-bed reactors provide significant advantages in the pharmaceutical synthesis. However, it is still challenging to develop suitable catalysts for flow processes. Conventional Pd- and Pt-based catalysts, the most commonly used in batch reactions, are inappropriate for flow reactions due to their irregular and fine particle sizes and also their chemo-selectivity issues, especially for halogen-substituted nitroarenes. To overcome these limitations, we designed a scalable flow process using a Co/Al 2 O 3 heterogeneous catalyst, which achieved high chemo-selectivity for various nitroarenes, regardless of substituent type or position. The catalyst was supported on uniform spherical Al 2 O 3 carriers with tailored particle size and narrow size distribution, which minimized the reactor pressure drop (Δ P ) and ensured stable operation. In particular, long-term hydrogenation of p -chloronitrobenzene to p -chloroaniline maintained full conversion and high selectivity (>97% at 80 °C) over 180 h with negligible Δ P . This work therefore establishes a robust and versatile catalytic platform for nitro-group hydrogenation, offering industrial relevance for active pharmaceutical ingredient (API) manufacturing.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: